Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Emerging Therapy and TPP Insights

Thelansis's "Metastatic Castration-Resistant Prostate Cancer (mCRPC) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Overview

Metastatic Castration-Resistant Prostate Cancer (mCRPC) represents an advanced and aggressive stage of prostate cancer characterized by disease progression despite castrate levels of testosterone achieved through androgen deprivation therapy. The condition is driven by persistent androgen receptor signaling and alternative resistance mechanisms, enabling continued tumor growth and metastatic spread.

Clinically, mCRPC predominantly metastasizes to bone and lymph nodes, leading to significant complications such as bone pain, fractures, spinal cord compression, and systemic symptoms including fatigue and functional decline. These manifestations substantially impact patient quality of life and contribute to high morbidity.

The current treatment landscape is multifaceted, incorporating next-generation androgen receptor pathway inhibitors, chemotherapy, radiopharmaceuticals, and supportive care. While these therapies have improved overall survival, treatment resistance and disease progression remain inevitable for most patients, highlighting the limitations of existing options. Consequently, mCRPC remains a major focus of oncology innovation, with ongoing development of targeted therapies, immunotherapies, radioligand therapies, and combination strategies aimed at improving durability of response and personalizing treatment approaches.

Key Highlights

• In Italy, the diagnosed mCRPC patient pool is projected to increase from 37.5K in 2025 to 39.4K by 2035, indicating modest growth (0.5% CAGR) driven by aging population and improved survival.
• Disease progression and therapeutic resistance remain key challenges, with most patients eventually exhausting available treatment options.
• Increasing focus on precision oncology, radioligand therapies, and combination treatment strategies is expected to significantly evolve the future treatment landscape.

Market Overview

• The Germany mCRPC market is projected to grow from $342M in 2025 to $538M by 2035, reflecting steady growth driven by continued adoption of novel oncology therapies.
• Market expansion is supported by:
• Uptake of next-generation androgen receptor inhibitors and radiopharmaceuticals
• Increasing use of combination and sequential treatment strategies
• Despite relatively modest patient growth (0.5% CAGR), market growth is driven by high-value therapies and extended treatment duration.
• Future growth will depend on the successful integration of precision medicine approaches and novel modalities that improve survival outcomes and delay resistance.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Bristol-Myers Squibb
• K36 Therapeutics, Inc.
• Janux Therapeutics
• Janssen Pharmaceutical
• Celgene
• AstraZeneca
• POINT Biopharma
• Amgen
• TechnoGenesys, Inc.
• Pfizer
• Merck Sharp & Dohme LLC
• Daiichi Sankyo
• Aragon Pharmaceuticals, Inc.
• AbbVie
• BioNTech SE
• Hoffmann-La Roche
• Fusion Pharmaceuticals Inc.
• Syncromune, Inc.
• Astellas Pharma Global Development, Inc.
• Arsenal Biosciences, Inc.
• Atridia Pty Ltd.
• Shanghai AbelZeta Ltd.
• Regeneron Pharmaceuticals
• Bayer
• Novartis Pharmaceuticals
• Tasly Pharmaceutical Group Co., Ltd
• Blue Earth Therapeutics Ltd
• Inmune Bio, Inc.
• Celcuity Inc
• Pathos AI, Inc.
• IntoCell, Inc
• Orano Med LLC
• Nuvation Bio Inc.